Financial insights of MRVI

MyFinsight

For the quarter ending 2025-09-30, MRVI made $41,630K in revenue. -$25,556K in net income. Net profit margin of -61.39%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Revenue	41,630	47,397	46,850	65,200
Cost of revenue	35,975	39,629	39,125	36,826
Gross profit	5,655	-	-	-
Selling, general and administrative	35,396	38,575	39,564	39,087
Research and development	3,844	4,882	4,888	4,344
Change in estimated fair value of contingent consideration	60	140	-	-178
Goodwill impairment	0	30,449	12,435	154,239
Restructuring	7,386	0	-	-4
Total operating expenses	46,686	113,675	96,012	234,314
Loss from operations	-41,031	-66,278	-49,162	-169,114
Interest expense	6,844	6,815	6,778	13,634
Interest income	2,797	3,030	3,225	7,071
Change in payable to related parties pursuant to the tax receivable agreement	0	-	-	39
Other (expense) income	-71	-4,062	24	72
Loss before income taxes	-45,149	-74,125	-52,691	-175,644
Income tax (benefit) expense	-92	-4,288	162	311
Net loss	-45,057	-69,837	-52,853	-175,955
Net loss attributable to non-controlling interests	-19,501	-30,246	-22,908	-76,917
Net loss attributable to maravai lifesciences holdings, inc	-25,556	-39,591	-29,945	-99,038

Net loss per class a common share attributable to maravai lifesciences holdings, inc., basic (in usd per share)	-0.18	-0.27	-0.21	-0.7
Net loss per class a common share attributable to maravai lifesciences holdings, inc., diluted (in usd per share)	-0.18	-0.27	-0.21	-0.7
Weighted average number of class a common shares outstanding, basic (in shares)	144,683,000	144,236,000	143,425,000	141,555,000
Weighted average number of class a common shares outstanding, diluted (in shares)	144,683,000	144,236,000	143,425,000	141,555,000